AZN SEC Filings: 8-K, 10-Q, S-3 & 424B – AstraZeneca

Financials

TYPE

HEADLINE

FILED AT

11-K

Form 11-K - Annual report of employee stock purchase, savings and similar plans

Jun 29, 2026

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Feb 24, 2026

11-K

Form 11-K - Annual report of employee stock purchase, savings and similar plans

Jun 26, 2025

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Feb 18, 2025

11-K

Form 11-K - Annual report of employee stock purchase, savings and similar plans

Jun 26, 2024

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Feb 20, 2024

News

TYPE

HEADLINE

FILED AT

6-K

AstraZeneca PLC Announces Admission of Further Securities to Trading

Nov 2, 2026

6-K

AstraZeneca PLC Announces Total Voting Rights and Issued Share Capital as of October 31, 2026

Nov 2, 2026

6-K

AstraZeneca Reports Q3 and 9M 2026 Results with 7% Total Revenue Growth and Completed $2bn Summit Therapeutics Investment

Oct 30, 2026

6-K

Enhertu Approved in EU as Adjuvant Treatment for HER2-Positive Early Breast Cancer

Oct 27, 2026

6-K

Ultomiris Approved in US for IgAN

Oct 22, 2026

6-K

AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics

Oct 5, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B2

Form 424B2 - Prospectus [Rule 424(b)(2)]

Feb 27, 2026

424B2

Form 424B2 - Prospectus [Rule 424(b)(2)]

Feb 25, 2026

424B2

$5,000,000,000

Feb 23, 2024

424B2

Registration

Feb 21, 2024

424B2

$2,250,000,000

Mar 2, 2023

424B2

6,166

Feb 28, 2023

Registrations

TYPE

HEADLINE

FILED AT

8-A12B

Form 8-A12B - Registration of securities [Section 12(b)]

Mar 3, 2026

FWP

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

Feb 25, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 3, 2026

8-A12B

Form 8-A12B - Registration of securities [Section 12(b)]

Jan 22, 2026

8-A12B

Form 8-A12B - Registration of securities [Section 12(b)]

Jan 22, 2026

F-6

Form F-6 - Registration of American Depository Receipt shares, not immediately effective

Jan 21, 2025

Proxies

TYPE

HEADLINE

FILED AT

DFAN14A

Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material

Mar 19, 2024

Ownerships

TYPE

HEADLINE

FILED AT

Sharma Mani (Reporting)

Oct 8, 2026

Sharma Mani (Reporting)

Sep 11, 2026

Sharma Mani (Reporting)

Aug 7, 2026

Sharma Mani (Reporting)

Jul 8, 2026

Sharma Mani (Reporting)

Jun 16, 2026

Sharma Mani (Reporting)

May 22, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Feb 6, 2025

CORRESP

Form CORRESP - Correspondence

Jan 10, 2024

EFFECT

Form EFFECT - Notice of Effectiveness

Apr 13, 2021

CORRESP

Form CORRESP - Correspondence

Apr 8, 2021

LETTER

Form UPLOAD - SEC-generated letter

Mar 1, 2021

EFFECT

Form EFFECT - Notice of Effectiveness

Feb 7, 2020

AstraZeneca PLC AZN · SEC Filings